KRAS and non-small cell lung carcinoma: Sotorasib is a novel KRAS-G12C inhibitor, and approved for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy (Blair 2021).